Linked Life Data

12532665

Source:http://linkedlifedata.com/resource/pubmed/id/12532665

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
52
pubmed:dateCreated
2003-1-20
pubmed:abstractText
Based on the improved insight into the mechanism of blood coagulation in vivo, recombinant factor VIIa (rFVIIa) has been developed as a pro-haemostatic agent. It has been shown that this treatment is effective in patients with haemophilia and an inhibiting antibody against a coagulation factor. Administration of rFVIIa can be effective in the treatment of bleeding episodes and the prevention of perioperative blood loss in a number of other coagulation disorders as well. Initial clinical studies indicate that administration of rFVIIa may also reduce blood loss in patients with severe bleeding without pre-existent abnormalities in blood coagulation, but this requires confirmation in additional clinical trials.
pubmed:commentsCorrections
pubmed:language
dut
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0028-2162
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
146
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2534-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
pubmed:affiliation
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Inwendige Geneeskunde, Meibergdreef 9, 1105 AZ Amsterdam. m.m.levi@amc.uva.nl
pubmed:publicationType
Journal Article, English Abstract, Review